| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NPPC |
| Uniprot No | P23582 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-126aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSKPGAPPK VPRTPPAEEL AEPQAAGGGQ KKGDKAPGGG GANLKGDRSR LLRDLRVDTK SRAAWARLLQ EHPNARKYKG ANKKGLSKGC FGLKLDRIGS MSGLGC |
| 预测分子量 | 13 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于NPPC重组蛋白研究的参考文献示例(文献信息为虚构，仅供格式参考)：
1. **文献名称**：*Expression and Purification of Recombinant NPPC in E. coli for Functional Studies*
**作者**：Chen L, et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化了具有生物活性的重组NPPC蛋白，通过体外细胞实验验证其激活NPR2受体信号通路的能力，为后续机制研究提供基础。
2. **文献名称**：*Recombinant NPPC Ameliorates Cartilage Degeneration in Osteoarthritis Model Mice*
**作者**：Wang X, et al.
**摘要**：利用哺乳动物细胞系统制备重组NPPC蛋白，发现其通过抑制炎症因子释放和促进软骨细胞增殖，显著缓解小鼠骨关节炎模型的病理进展。
3. **文献名称**：*Structural Basis of NPPC-NPR2 Interaction Revealed by Cryo-EM*
**作者**：Sato H, et al.
**摘要**：通过冷冻电镜解析重组NPPC蛋白与其受体NPR2的复合物结构，阐明二者特异性结合的分子机制，为靶向药物设计提供结构依据。
---
**注**：以上文献为示例模板，实际研究中建议通过PubMed、Web of Science等数据库检索真实文献(关键词：*recombinant NPPC protein* / *NPPC expression*)。真实文献可能涉及NPPC在骨发育、心血管调节或生殖系统中的作用机制研究。
NPPC (C-type natriuretic peptide) is a member of the natriuretic peptide family, which includes hormones critical for regulating fluid balance, cardiovascular homeostasis, and tissue remodeling. Encoded by the *NPPC* gene, it is synthesized as a prepropeptide and processed into a 22-amino acid mature peptide. Unlike ANP and BNP (which primarily act as endocrine hormones), CNP functions mainly as a paracrine/autocrine signaling molecule, binding to the NPR-B receptor to stimulate intracellular cGMP production. This pathway influences diverse physiological processes, including endochondral bone growth, vascular relaxation, and extracellular matrix remodeling.
Recombinant NPPC refers to the engineered form of CNP produced using biotechnological systems, such as *E. coli* or mammalian cell cultures. Its development stems from therapeutic interest in CNP’s role in skeletal development disorders like achondroplasia, the most common form of dwarfism. Mutations in the FGFR3 gene cause excessive inhibition of bone growth, and CNP/NPR-B signaling has been shown to counteract this pathway, promoting chondrocyte proliferation and longitudinal bone growth. Beyond skeletal applications, recombinant NPPC is explored for cardiovascular diseases, fibrosis, and inflammatory conditions due to its vasodilatory and anti-proliferative properties.
However, therapeutic use faces challenges, such as CNP’s short plasma half-life (minutes) due to enzymatic degradation and renal clearance. Strategies to enhance stability include PEGylation, fusion proteins, or sustained-release formulations. Early-phase clinical trials for achondroplasia (e.g., Vosoritide, a CNP analog) demonstrate proof of concept, though long-term efficacy and safety require further validation. Research also investigates tissue-specific delivery systems and combination therapies to optimize bioavailability. As a biologic agent, recombinant NPPC represents a promising tool for precision medicine in growth disorders and regenerative therapies.
×
